Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans

REGENEREX PHARMA, INC.

Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.
Claims 95% of chronic wounds show 100% closure within 90 days in clinical evaluations.
Manufacturing to begin in Q4 2023 at facility in Memphis, TN.
No specific management officer or director names were provided in the update.
Products are FDA-cleared or OTC; Accelerex is a prescription-only combination device.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.